Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines : Questions médicales fréquentes
Nom anglais: Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
Descriptor UI:D051778
Tree Number:D12.776.930.127.092
Termes MeSH sélectionnés :
Prostatic Neoplasms
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines : Questions médicales les plus fréquentes",
"headline": "Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-09",
"dateModified": "2025-04-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Facteurs de transcription à motif basique et à glissière à leucines",
"url": "https://questionsmedicales.fr/mesh/D050976",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs de transcription à motif basique et à glissière à leucines",
"code": {
"@type": "MedicalCode",
"code": "D050976",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930.127"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Facteur de transcription associé à la microphtalmie",
"alternateName": "Microphthalmia-Associated Transcription Factor",
"url": "https://questionsmedicales.fr/mesh/D051739",
"about": {
"@type": "MedicalCondition",
"name": "Facteur de transcription associé à la microphtalmie",
"code": {
"@type": "MedicalCode",
"code": "D051739",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930.127.092.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine du proto-oncogène N-Myc",
"alternateName": "N-Myc Proto-Oncogene Protein",
"url": "https://questionsmedicales.fr/mesh/D000071447",
"about": {
"@type": "MedicalCondition",
"name": "Protéine du proto-oncogène N-Myc",
"code": {
"@type": "MedicalCode",
"code": "D000071447",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930.127.092.625"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéines de liaison à l'élément de régulation des stérols",
"alternateName": "Sterol Regulatory Element Binding Proteins",
"url": "https://questionsmedicales.fr/mesh/D051779",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de liaison à l'élément de régulation des stérols",
"code": {
"@type": "MedicalCode",
"code": "D051779",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930.127.092.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéine-1 de liaison à l'élément de régulation des stérols",
"alternateName": "Sterol Regulatory Element Binding Protein 1",
"url": "https://questionsmedicales.fr/mesh/D051780",
"about": {
"@type": "MedicalCondition",
"name": "Protéine-1 de liaison à l'élément de régulation des stérols",
"code": {
"@type": "MedicalCode",
"code": "D051780",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930.127.092.750.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine-2 de liaison à l'élément de régulation des stérols",
"alternateName": "Sterol Regulatory Element Binding Protein 2",
"url": "https://questionsmedicales.fr/mesh/D051782",
"about": {
"@type": "MedicalCondition",
"name": "Protéine-2 de liaison à l'élément de régulation des stérols",
"code": {
"@type": "MedicalCode",
"code": "D051782",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930.127.092.750.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Facteur-3 de transcription",
"alternateName": "Transcription Factor 3",
"url": "https://questionsmedicales.fr/mesh/D058127",
"about": {
"@type": "MedicalCondition",
"name": "Facteur-3 de transcription",
"code": {
"@type": "MedicalCode",
"code": "D058127",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930.127.092.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines",
"alternateName": "Basic Helix-Loop-Helix Leucine Zipper Transcription Factors",
"code": {
"@type": "MedicalCode",
"code": "D051778",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Muhammad Waseem",
"url": "https://questionsmedicales.fr/author/Muhammad%20Waseem",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Plant Hormones and Development Regulation of Chongqing, School of Life Sciences, Chongqing University, Chongqing, China."
}
},
{
"@type": "Person",
"name": "Zhengguo Li",
"url": "https://questionsmedicales.fr/author/Zhengguo%20Li",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Plant Hormones and Development Regulation of Chongqing, School of Life Sciences, Chongqing University, Chongqing, China."
}
},
{
"@type": "Person",
"name": "Bao-Teng Wang",
"url": "https://questionsmedicales.fr/author/Bao-Teng%20Wang",
"affiliation": {
"@type": "Organization",
"name": "College of Biology and the Environment, Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, China."
}
},
{
"@type": "Person",
"name": "Miao Zhuang",
"url": "https://questionsmedicales.fr/author/Miao%20Zhuang",
"affiliation": {
"@type": "Organization",
"name": "College of Biology and the Environment, Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, China."
}
},
{
"@type": "Person",
"name": "Zhi-Min Zhang",
"url": "https://questionsmedicales.fr/author/Zhi-Min%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "College of Biology and the Environment, Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Presence of HPV in prostate tissue from patients submitted to prostate biopsy.",
"datePublished": "2023-01-13",
"url": "https://questionsmedicales.fr/article/36651430",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/acb371205"
}
},
{
"@type": "ScholarlyArticle",
"name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.",
"datePublished": "2022-09-24",
"url": "https://questionsmedicales.fr/article/36253300",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clgc.2022.09.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "The mendelian randomized study revealed the association of prostatitis with prostate cancer risk.",
"datePublished": "2024-10-20",
"url": "https://questionsmedicales.fr/article/39428439",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-76355-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.",
"datePublished": "2023-05-26",
"url": "https://questionsmedicales.fr/article/37271051",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cmpb.2023.107624"
}
},
{
"@type": "ScholarlyArticle",
"name": "Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.",
"datePublished": "2023-03-14",
"url": "https://questionsmedicales.fr/article/36917412",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11255-023-03531-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Facteurs de transcription",
"item": "https://questionsmedicales.fr/mesh/D014157"
},
{
"@type": "ListItem",
"position": 5,
"name": "Facteurs de transcription à motif basique et à glissière à leucines",
"item": "https://questionsmedicales.fr/mesh/D050976"
},
{
"@type": "ListItem",
"position": 6,
"name": "Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines",
"item": "https://questionsmedicales.fr/mesh/D051778"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines",
"description": "Comment diagnostiquer une anomalie des facteurs de transcription ?\nQuels tests sont utilisés pour évaluer ces facteurs ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nPeut-on détecter ces facteurs dans le sang ?\nQuels marqueurs sont associés à ces facteurs ?",
"url": "https://questionsmedicales.fr/mesh/D051778?mesh_terms=Prostatic+Neoplasms&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines",
"description": "Quels symptômes sont liés aux dysfonctionnements de ces facteurs ?\nLes symptômes varient-ils selon le type de facteur ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes apparaissent-ils à un âge spécifique ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D051778?mesh_terms=Prostatic+Neoplasms&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines",
"description": "Comment prévenir les anomalies des facteurs de transcription ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes vaccinations peuvent-elles aider ?\nLe dépistage prénatal est-il utile ?\nY a-t-il des recommandations pour les femmes enceintes ?",
"url": "https://questionsmedicales.fr/mesh/D051778?mesh_terms=Prostatic+Neoplasms&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines",
"description": "Quels traitements sont disponibles pour les anomalies ?\nLa thérapie génique est-elle efficace ?\nDes traitements préventifs existent-ils ?\nLes médicaments peuvent-ils corriger les anomalies ?\nY a-t-il des essais cliniques en cours ?",
"url": "https://questionsmedicales.fr/mesh/D051778?mesh_terms=Prostatic+Neoplasms&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines",
"description": "Quelles complications peuvent survenir avec ces anomalies ?\nLes complications sont-elles toujours graves ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être évitées ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D051778?mesh_terms=Prostatic+Neoplasms&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines",
"description": "Quels sont les facteurs de risque pour ces anomalies ?\nL'âge parental influence-t-il le risque ?\nLes habitudes de vie affectent-elles le risque ?\nY a-t-il des tests pour évaluer le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D051778?mesh_terms=Prostatic+Neoplasms&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des facteurs de transcription ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer ces facteurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'ADN et les techniques de PCR sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Parfois, des biopsies peuvent être nécessaires pour évaluer l'expression des gènes."
}
},
{
"@type": "Question",
"name": "Peut-on détecter ces facteurs dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Généralement, ils sont évalués dans des échantillons de tissus plutôt que dans le sang."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés à ces facteurs ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs spécifiques de l'expression génique peuvent indiquer des anomalies."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux dysfonctionnements de ces facteurs ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles du développement, des anomalies métaboliques ou des cancers peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de facteur ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent du type de facteur de transcription impliqué."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies de croissance ou des troubles hormonaux peuvent être des indicateurs."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils à un âge spécifique ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent apparaître à la naissance, d'autres plus tard dans l'enfance."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la nature de l'anomalie et du traitement appliqué."
}
},
{
"@type": "Question",
"name": "Comment prévenir les anomalies des facteurs de transcription ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par le conseil génétique et la détection précoce."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé génétique, mais ne prévient pas toutes les anomalies."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas directement les anomalies génétiques."
}
},
{
"@type": "Question",
"name": "Le dépistage prénatal est-il utile ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage prénatal peut identifier certaines anomalies génétiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les femmes enceintes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes enceintes devraient suivre des soins prénatals réguliers et un bon mode de vie."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les anomalies ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des thérapies géniques ou des médicaments ciblés."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être efficace pour certaines anomalies génétiques, mais pas pour toutes."
}
},
{
"@type": "Question",
"name": "Des traitements préventifs existent-ils ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils génétiques peuvent aider à prévenir certaines anomalies héréditaires."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils corriger les anomalies ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent cibler les voies de signalisation affectées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques en cours ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux essais cliniques explorent de nouvelles thérapies pour ces anomalies."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces anomalies ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des troubles métaboliques ou des cancers."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles toujours graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, certaines anomalies peuvent être gérées avec succès."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines anomalies peuvent entraîner des complications chroniques."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un traitement précoce."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent avoir un impact significatif sur la qualité de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour ces anomalies ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines expositions environnementales sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge parental influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé des parents peut augmenter le risque d'anomalies génétiques."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie affectent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines peuvent réduire certains risques d'anomalies."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests pour évaluer le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques peuvent évaluer le risque d'anomalies héréditaires."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines substances chimiques peut augmenter le risque."
}
}
]
}
]
}
Prostate cancer (PCa) is the second most frequent cancer among men in the Western population. Infections, such as the one caused by the human papillomavirus (HPV), have been shown to promote inflammat...
Prostate tissue fragments were collected by prostate biopsy and subjected to polymerase chain reaction with primers for the HPV L1 gene to identify the presence of the virus....
Among 162 patients, 10 (6.2%) had HPV and in 152 (93.8%) HPV was not identified in prostate biopsies. HPV was detected in 7/95 (7.4%) of patients with PCa, in 2/55 (3.6%) of patients without PCa, and ...
There were no significant levels of HPV L1 protein in prostate tissue. The findings suggest the absence of HPV oncogenic activity in the prostate tissue of patients with PCa....
In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals....
This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ...
It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high...
As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...
In recent observational studies, a potential link between prostatitis and prostate cancer (PCa) has been hinted at, yet the causality remains ambiguous. In our endeavor to scrutinize the conceivable c...
With emerging evidence to improve prostate cancer (PCa) screening, multiparametric magnetic prostate imaging is becoming an essential noninvasive component of the diagnostic routine. Computer-aided di...
We collected 1647 fine-grained biopsy-confirmed findings, including Gleason scores and prostatitis, to form a training dataset. In our experimental framework for lesion detection, all models utilized ...
An optimal model configuration with fine class granularity (prostatitis included) and OHE has scored the lesion-wise partial Free-Response Receiver Operating Characteristic (FROC) area under the curve...
This paper examines several configurations for model training in the biparametric MRI setup and proposes optimal value ranges. It also shows that the fine-grained class configuration, including prosta...
To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced n...
The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients wit...
In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with ...
A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biops...
Financial toxicity (FT) is a growing concern among cancer survivors that adversely affects the quality of life and survival. Individuals diagnosed with aggressive cancers are often at a greater risk o...
PCa patients enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP) were recontacted for long-term follow-up. The prevalence of FT in the PCaP cohort was estimated. FT was estimated u...
More than one-third of PCa patients reported experiencing FT. PCa aggressiveness was significantly independently associated with high FT; high aggressive PCa at diagnosis had more than twice the risk ...
Aggressive PCa was associated with high FT. Future studies should collect more information about the characteristics of men with high FT and identify additional risk factors of FT....
Prostate-specific membrane antigen (PSMA) hybrid imaging is a promising new technique gaining importance in the field of prostate cancer (PCa) diagnosis and treatment planning. By combining PSMA radio...
Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investiga...
Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively qu...
Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (114...
The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger canc...
Purpose: Determine the time-dependent magnitude of intrafraction prostate displacement and a cutoff for the tracking decision. Methods: Nine patients with localized prostate cancer were treated with u...
Apart from other risk factors, chronic inflammation is also associated with the onset of Prostate Cancer (PCa), wherein pathogen infection and tissue microbiome dysbiosis are known to play a major rol...